Retinal Biologics Market: Key Drivers and Opportunities
These treatments offer targeted action, minimizing systemic side effects and potentially improving visual outcomes. For instance, drugs like Vabysmo target both VEGF-A, and Ang-2 pathways?.
The prevalence of VEGF-A antagonists, and TNF-A inhibitors is also perceived as an influential market trend. The former, including ranibizumab, aflibercept, and the recently approved faricimab-svoa (Vabysmo), have shown particularly successful in treating wet age-related macular degeneration, and diabetic macular edema.